This clinical trial, sponsored by Washington University School of Medicine, aims to evaluate the efficacy of tirzepatide in treating Crohn's disease, particularly in patients with difficult-to-treat inflammation. The market for Crohn's disease therapies is competitive, with established biologics such as anti-TNF agents and newer therapies like JAK inhibitors and IL-23 inhibitors. Tirzepatide's novel mechanism may provide a differentiated therapeutic option, potentially capturing market share from existing treatments. The trial's success could enhance the commercial viability of tirzepatide in inflammatory bowel disease (IBD) and expand its indications beyond metabolic disorders. Diligence considerations should focus on patient recruitment, regulatory pathways, and potential market access challenges.